Lenvatinib in Management of Solid Tumors.

Area of Science:

• Oncology
• Pharmacology

Background:

• Lenvatinib is a potent tyrosine kinase inhibitor with antiangiogenic properties.
• It is approved for differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma.
• Lenvatinib shows promise in other cancers like endometrial and thyroid cancer.

Purpose of the Study:

• To provide an update on lenvatinib's FDA approvals and off-label uses.
• To discuss lenvatinib's efficacy, side effects, and predictive biomarkers.
• To explore the combination of lenvatinib with pembrolizumab in various malignancies.

Main Methods:

• Review of FDA approvals and clinical trial data.
• Analysis of lenvatinib's pharmacokinetic and pharmacodynamic properties.
• Exploration of combination therapy with immune checkpoint inhibitors.

Main Results:

• Lenvatinib is approved for specific cancers and shows potential in others.
• The combination of lenvatinib and pembrolizumab is being investigated for multiple cancers.
• Understanding side effects and optimizing dosage are crucial for patient tolerance.

Conclusions:

• Lenvatinib is an effective antiangiogenic agent with broad applicability in oncology.
• Combination therapies, particularly with pembrolizumab, hold significant promise for improved treatment outcomes.
• Further research is needed to optimize dosing, identify predictive biomarkers, and manage long-term toxicities.